97299 ⎘
Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen Inducing cell proliferation
Trispecific T cell Engagers
#2ANTI-CD3 ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND CD3 AND CD20, AND USES THEREOF
#3CLEC9A BINDING AGENTS
#4ANTIBODIES SPECIFIC TO HUMAN NECTIN-2
#5AGONISTIC ANTIBODIES THAT BIND HUMAN CD40 AND USES THEREOF
#6ANTI-FGFR2 ANTIBODIES IN COMBINATION WITH CHEMOTHERAPY AGENTS IN CANCER TREATMENT
#7CD8 BINDING AGENTS
#8ANTI-TIRC7 ANTIGEN BINDING PROTEINS
#9BISPECIFIC T CELL ENGAGERS
#10MATERIALS AND METHODS FOR MODULATING DELTA CHAIN MEDIATED IMMUNITY
#11CHECKPOINT REGULATOR ANTAGONISTS
#12ANTI-PD-L1 ANTIBODIES, COMPOSITIONS AND ARTICLES OF MANUFACTURE
#13ANTI-VISTA ANTIBODIES AND FRAGMENTS
#14ANTI-PD-L1 ANTIBODIES AND METHODS OF USE THEREOF
#15ANTI-HUMAN VISTA ANTIBODIES AND USE THEREOF
#16ANTI-PVRIG ANTIBODIES AND METHODS OF USE
#17ANTIBODIES AGAINST TIM3 AND USES THEREOF
#18COVALENTLY BONDED DIABODIES HAVING IMMUNOREACTIVITY WITH PD-1 AND LAG-3, AND METHODS OF USE THEREOF
#19ANTI-IGF-1 RECEPTOR HUMANIZED ANTIBODY
#20ANTI-HUMAN VISTA ANTIBODIES AND USE THEREOF
#21ANTI-HUMAN VISTA ANTIBODIES AND USE THEREOF
#22METHODS AND COMPOSITIONS FOR TREATING CANCER
#23ENGRAFTMENT OF STEM CELLS WITH A COMBINATION OF AN AGENT THAT TARGETS STEM CELLS AND MODULATION OF IMMUNOREGULATORY SIGNALING
#24ENGINEERED ANTI-IL-2 ANTIBODIES
#25COMPOSITIONS AND METHODS FOR TREATING CANCER
#26COMBINATION THERAPY FOR THE TREATMENT OF CANCER
#27COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY
#28ANTI-FLT3 ANTIBODIES AND COMPOSITIONS
#29LAIR-1-BINDING AGENTS AND METHODS OF USE THEREOF
#30Methods For Prevention Of Graft Rejection In Xenotransplantation
#31BEADS FOR TARGETED SIGNAL DELIVERY
#32ANTIBODY VARIANTS
#33ANTIBODIES AGAINST TIM3 AND USES THEREOF
#34AGONISTIC ANTIBODIES THAT BIND CD40
#35VISTA ANTAGONIST AND METHODS OF USE
#36CHIMERIC POXVIRUS COMPOSITIONS AND USES THEREOF
#37ANTI-CD28 X ANTI-TROP2 ANTIBODIES
#38ANTI P2X7 RECEPTOR ANTIBODIES AND FRAGMENTS THEREOF
#39ANTIBODY MOLECULES TO PD-1 AND USES THEREOF
#40ANTI-TIGIT ANTIBODIES
#41Anti-CD112R Compositions and Methods
#42CD47/4-1BB-TARGETING PROTEIN COMPLEX AND METHODS OF USE THEREOF
#43Antigen-Presenting Synthetic Surfaces, Covalently Functionalized Surfaces, Activated T Cells, and Uses Thereof
#44NON-CYTOTOXIC MODIFIED CELLS AND USE THEREOF
#45ANTI-CD39 ANTIBODIES, COMPOSITIONS COMPRISING ANTI-CD39 ANTIBODIES AND METHODS OF USING ANTI-CD39 ANTIBODIES
#46Binding agents and methods of using the same
#47AGENTS THAT ENGAGE ANTIGEN-PRESENTING CELLS THROUGH DENDRITIC CELL ASIALOGLYCOPROTEIN RECEPTOR (DC-ASGPR)
#48ANTI-CD122 ANTIBODIES, ANTI-CD132 ANTIBODIES, AND RELATED BISPECIFIC BINDING PROTEINS
#49Trispecific T cell Engagers
#50IL-18BP ANTAGONIST ANTIBODIES AND THEIR USE IN MONOTHERAPY AND COMBINATION THERAPY IN THE TREATMENT OF CANCER
#51Binding Molecules Targeting IL-2 Receptor
#52AUGMENTATION OF INNATE AND ADAPTIVE IMMUNITY BY INHIBITION OF INTERACTION OF LILRBS WITH MHC-1
#53PARTIAL AGONISTS OF INTERLEUKIN-2, NUCLEIC ACIDS ENCODING THE SAME, AND METHODS OF USE THEREOF
#54MULTIMERIC T-CELL MODULATORY POLYPEPTIDES AND METHODS OF USE THEREOF
#55IMMUNE-STIMULATING HUMANIZED MONOCLONAL ANTIBODIES AGAINST HUMAN INTERLEUKIN-2, AND FUSION PROTEINS THEREOF
#56ANTI-FAMILY WITH SEQUENCE SIMILARITY 19, MEMBER A5 ANTIBODIES AND METHOD OF USE THEREOF
#57Anti-CD3 Antibodies, Bispecific Antigen-Binding Molecules that Bind CD3 and CD20, and Uses Thereof
#58Bispecific T cell Engagers
#59Bispecific Asymmetric Heterodimers Comprising Anti-CD3 Constructs
#60FLT3-BINDING CHIMERIC ANTIGEN RECEPTORS, CELLS, AND USES THEREOF
#61ANTI-CD3 ANTIBODY AND USE THEREOF
#62TARGETING CYTOTOXIC CELLS WITH CHIMERIC RECEPTORS FOR ADOPTIVE IMMUNOTHERAPY
#63ANTI-CD25 ANTIBODY AGENTS
#64SELECTIVE TARGETING OF OLIGOMERIC B-AMYLOID
#65RECOMBINANT PROTEINACEOUS BINDING MOLECULES
#66BISPECIFIC FUSION PROTEIN
#67TARGETED ADAM17 BLOCKER COMPOUNDS, ANTI-ADAM17 ANTIBODIES, METHODS OF MAKING, AND METHODS OF USING
#68COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY
#69Antibodies binding PD-1 and uses thereof
#70GPRC5D CHIMERIC ANTIGEN RECEPTORS AND CELLS EXPRESSING THE SAME
#71CLEC12AXCD3 BISPECIFIC ANTIBODIES AND METHODS FOR THE TREATMENT OF DISEASE
#72BISPECIFIC NK CELL AGONIST, PREPARATION METHOD, AND APPLICATION
#73Agents for Treatment of Claudin Expressing Cancer Diseases
#74METHODS FOR EXPANSION OR DEPLETION OF T-REGULATORY CELLS
#75ANTIBODIES AGAINST TIM3 AND USES THEREOF
#76METHODS TO PROTECT TRANSPLANTED TISSUE FROM REJECTION
#77ANTI-TIGIT ANTIBODIES AND METHODS OF USE THEREOF
#78ANTI-HUMAN VISTA ANTIBODIES AND USE THEREOF
#79BINDING AGENTS AND METHODS OF USING THE SAME
#80Anti-PVRIG antibodies and methods of use
#81Engineered anti-IL-2 antibodies
#82Compositions and methods for immunotherapy
#83ANTI-FLT-1 ANTIBODIES FOR TREATING DUCHENNE MUSCULAR DYSTROPHY
#84ANTI-HUMAN VISTA ANTIBODIES AND USE THEREOF
#85PVRIG POLYPEPTIDES AND METHODS OF TREATMENT
#86Antibodies against TIM3 and uses thereof
#87NOVEL ANTI-PD-1 ANTIBODIES
#88VISTA MODULATORS FOR DIAGNOSIS AND TREATMENT OF CANCER
#89INERT FORMAT
#90CHECKPOINT REGULATOR ANTAGONISTS
#91ANTI-PD-L1 ANTIBODIES, COMPOSITIONS AND ARTICLES OF MANUFACTURE
#92ANTI-CD277 ANTIBODIES AND USES THEREOF
#93Monoclonal Antibodies to Programmed Death 1 (PD-1)
#94Bispecific Anti-PSMA x Anti-CD28 Antibodies and Uses Thereof
#95Bifunctional molecule and use thereof
#96BISPECIFIC HETERODIMERIC FUSION PROTEINS CONTAINING IL-15 - IL-15Ralpha Fc-FUSION PROTEINS AND IMMUNE CHECKPOINT ANTIBODY FRAGMENTS
#97Antibodies binding TNFR2 and uses thereof
#98Engineered anti-IL-2 antibodies
#99CD8 BINDING AGENTS AND USES THEREOF
#100CD96-BINDING AGENTS AS IMMUNOMODULATORS
#101METHODS OF ADMINISTERING ANTI-OX40 ANTIBODIES
#102EX VIVO GAMMA DELTA T CELL POPULATIONS
#103Neutralizing anti-influenza binding molecules and uses thereof
#104METHODS OF ADMINISTERING ANTI-OX40 ANTIBODIES
#105RESTORATION OF T CELL ACTIVITY VIA THE CD39/CD73 AXIS
#106Engineered anti-il-2 antibodies
#107Antibodies to TGF-Beta
#108HUMAN MONOCLONAL ANTIBODIES TO PROGRAMMED DEATH LIGAND 1 (PD-L1)
#109ANTI-IL-1-BETA ANTIBODIES
#110SINGLE-AND MULTI-CHAIN POLYPEPTIDES THAT BIND SPECIFICALLY TO CD3 EPSILON
#111ANTI-TNFR2 ANTIBODY AND USES THEREOF
#112IMMUNOMODULATING TUMOR NECROSIS FACTOR RECEPTOR 25 (TNFR25) AGONISTS, ANTAGONISTS, AND IMMUNOTOXINS
#113ANTI-TCR DELTA VARIABLE 1 ANTIBODIES
#114Nucleic acids encoding and methods of producing proteins comprising antibody chains
#115BISPECIFIC ANTIBODIES SPECIFICALLY BINDING TO PD1 AND LAG3
#116METHODS FOR SELECTIVE EXPANSION OF GAMMA DELTA T-CELL POPULATIONS AND COMPOSITIONS THEREOF
#117Anti-CD39 Antibody Compositions and Methods
#118ANTIBODIES AND METHODS OF USE
#119ANTI-TIRC7 ANTIGEN BINDING PROTEINS
#120CLEC9A BINDING AGENTS
#121COMPOUND CHIMERIC ANTIGEN RECEPTOR (cCAR) TARGETING MULTIPLE ANTIGENS, COMPOSITIONS AND METHOD OF USE THEREOF
#122Engraftment of stem cells with a combination of an agent that targets stem cells and modulation of immunoregulatory signaling
#123MODIFIED FC REGION
#124Anti P2X7 receptor antibodies and fragments thereof
#125Immunomodulation and anti-tumor-related nanobody and nucleic acid encoding sequence thereof, and uses of the same
#126Anti-T-cell nanobody and nucleic acid encoding sequence thereof, and uses of the same
#127MATERIALS AND METHODS FOR MODULATING AN IMMUNE RESPONSE
#128EX VIVO GAMMA DELTA T CELL POPULATIONS
#129Antibodies directed against GDF-15
#130ANTIBODY TO LEPTIN RECEPTOR
#131ANTI-HUMAN VISTA ANTIBODIES AND USE THEREOF
#132ANTI-PD-1 ANTIBODIES AND METHODS OF USE THEREOF
#133RECOMBINANT FAP BINDING PROTEINS AND THEIR USE
#134ANTI-C-MET AGONIST ANTIBODY AND USE THEREOF
#135Bispecific polypeptides against CD137
#136IL15/IL15Ralpha HETERODIMERIC Fc-FUSION PROTEINS
#137HUMAN ANTIBODIES THAT BIND RET AND METHODS OF USE THEREOF
#138BINDING MOLECULES BINDING PD-L1 AND LAG-3
#139LAG-3 binding members
#140CD8 BINDING AGENTS
#141Anti-CD112R compositions and methods
#142Antibodies having specificity for BTN2 and uses thereof
#143Anti-MET antibodies and uses thereof
#144Agents that engage antigen-presenting cells through dendritic cell asialoglycoprotein receptor (DC-ASGPR)
#145Anti-PD-L1 antibodies and variants
#146ANTI-VISTA ANTIBODIES AND FRAGMENTS
#147Anti-PD1 and anti-CTLA4 antibodies
#148ANTIBODIES SPECIFIC TO HUMAN NECTIN-2
#149ANTI-OX40 ANTIBODIES AND METHODS OF USE THEREOF
#150ANTI-B7S1 POLYPEPTIDES AND THEIR USE
#151ANTI-TIGIT ANTIBODIES AND METHODS OF USE THEREOF
#152FCMR-binding molecules and uses thereof
#153Antibodies against TIM3 and uses thereof
#154MULTIMERIC T-CELL MODULATORY POLYPEPTIDES AND METHODS OF USE THEREOF
#155BISPECIFIC ANTIBODIES WITH TETRAVALENCY FOR A COSTIMULATORY TNF RECEPTOR
#156Antibodies binding to vista at acidic pH
#157Targeted heterodimeric Fc fusion proteins containing IL-15 IL-15alpha and antigen binding domains
#158CD73 BLOCKING ANTIBODIES
#159Anti-FGFR2 antibodies in combination with chemotherapy agents in gastric cancer
#160Combination Therapy for the Treatment of Cancer
#161Covalently Bonded Diabodies Having Immunoreactivity with PD-1 and LAG-3, and Methods of Use Thereof
#162LAIR-1-binding agents and methods of use thereof
#163Anti-CD27 and anti-PD-L1 antibodies and bispecific constructs
#164BIFUNCTIONAL MOLECULE DIRECTED AGAINST HUMAN PD-1
#165CLEC12AxCD3 bispecific antibodies and methods for the treatment of disease
#166ANTI-TIM-3 ANTIBODIES, COMPOSITIONS COMPRISING ANTI-TIM-3 ANTIBODIES AND METHODS OF MAKING AND USING ANTI-TIM-3 ANTIBODIES
#167Method of treatment with a fusion protein comprising apelin and an anti-APLNR antibody
#168Variant antibodies that bind OX40
#169INTERFERON RECEPTOR 1 ANTIBODIES AND THEIR USES
#170Anti-CD137 antibodies and method of treating colorectal cancer using them
#171ANTI-TCR ANTIBODY MOLECULES AND USES THEREOF
#172Anti PD-L1 antibodies
#173Vista antagonist and methods of use
#174Anti-PD-1 antibodies
#175Anti-VISTA antibodies and fragments
#176Anti-FLT3 antibodies and compositions
#177Bispecific Asymmetric Heterodimers Comprising Anti-CD3 Constructs
#178ANTI-HUMAN VISTA ANTIBODIES AND USE THEREOF
#179ANTI-HUMAN VISTA ANTIBODIES AND USE THEREOF
#180Anti-mesothelin antigen-binding molecules and uses thereof
#181Fusion proteins comprising an anti-CD40 antibody and cancer antigens
#182COMPOSITION AND METHODS FOR ANTI-TNFR2 ANTIBODIES
#183BISPECIFIC ANTIGEN BINDING MOLECULES WITH TRIVALENT BINDING TO CD40
#184MATERIALS AND METHODS FOR MODULATING DELTA CHAIN MEDIATED IMMUNITY
#185Trispecific T cell engagers
#186Anti-OX40 antibody
#187THERAPEUTIC OR PROPHYLACTIC AGENT FOR HTLV-1-ASSOCIATED MYELOPATHY (HAM), AND METHOD FOR TREATING HAM
#188Partial agonists of interleukin-2
#189Methods and compositions for treating cancer
#190METHOD FOR ACTIVATING IMMUNE RESPONSE OF TARGET CELL AND COMPOSITION THEREFOR
#191Anti-CD112R compositions and methods
#192Methods and compositions for treating cancer
#193COMBINATION THERAPIES COMPRISING CD137/HER2 BISPECIFIC AGENTS AND PD-1 AXIS INHIBITORS AND USES THEREOF
#194Immune-stimulating humanized monoclonal antibodies against human interleukin-2, and fusion proteins thereof
#195Polypeptides
#196DIMERIC PROTEIN WITH TRIPLE MUTATIONS
#197IMMUNE-STIMULATING MONOCLONAL ANTIBODIES AGAINST HUMAN INTERLEUKIN-2
#198ANTI-CD40 ANTIBODIES AND COMPOSITIONS
#199ANTI-CD27 AND ANTI-PD-L1 ANTIBODIES AND BISPECIFIC CONSTRUCTS
#200Anti PD-1 antibodies
#201Anti-PVRIG antibodies and methods of use
#202Modified bifunctional anti-human signal regulatory protein alpha (SIRPa) antibody and method of use thereof for treating cancer
#203Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
#204Use of SRSF3 agents for the treatment and/or prevention of neurological conditions, cancer, bacterial infections or viral infections
#205Anti-CD27 antibodies and uses thereof
#206ANTI-CD40 ANTIBODIES IN COMBINATION AND METHODS OF USE
#207Monoclonal antibodies that bind human CD161
#208COMPOSITION OF BISPECIFIC ANTIBODIES AND METHOD OF USE THEREOF
#209Anti-CD39 antibody compositions and methods
#210Anti-CEACAM antibodies and uses thereof
#211Neutralizing anti-influenza binding molecules and uses thereof
#212Methods and compositions for treating cancer
#213Anti-CD25 antibody agents
#214Anti-family with sequence similarity 19, member A5 antibodies and method of use thereof
#215Anti-CD25 for tumour specific cell depletion
#216Anti-CD25 for tumour specific cell depletion
#217ANTI-PD-L1 ANTIBODIES, COMPOSITIONS AND ARTICLES OF MANUFACTURE
#218Nucleic acids encoding anti-CD40 antibodies
#219Combination therapy involving antibodies against claudin 18.2 for treatment of metastatic pancreatic adenocarcinoma
#220Anti-CD39 antibodies
#221Anti-CD25 for tumour specific cell depletion
#222Anti-CD25 for tumour specific cell depletion
#223Anti-CD25 for tumour specific cell depletion
#224Anti-CD25 antibody agents
#225ANTI-CD3 ANTIBODIES AND METHODS OF USE THEREOF
#226CD137 antibodies for T-cell activation
#227Anti-CD25 antibody agents
#228BISPECIFIC ANTIBODIES TO MOSPD2 AND T CELL- OR NK CELL-SPECIFIC MOLECULES
#229Anti-CD73 antibodies and uses thereof
#230Antibodies against OX-40 and uses thereof
#231Agents for Treatment of Claudin Expressing Cancer Diseases
#232COMBINATORIAL ANTIBODY LIBRARIES AND USES THEREOF
#233HUMAN TNFRSF25 ANTIBODY
#234BISPECIFIC ANTI-CD3 X CD20 ANTIBODIES AND USES THEREOF
#235Anti-C10orf54 antibodies and uses thereof
#236PVRIG polypeptides and methods of treatment
#237Agonistic antibodies that bind human CD40 and uses thereof
#238Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
#239Anti-CD277 antibodies
#240Methods of inducing or enhancing an immune response comprising administering agonistic anti-CD40 antibodies
#241Anti-PD-1 antibodies and methods of use thereof
#242Methods for expansion or depletion of T-regulatory cells
#243Immunomodulating tumor necrosis factor receptor 25 (TNFR25) agonists, antagonists, and immunotoxins
#244Antibody molecules to PD-1 and uses thereof
#245MODULATION OF T CELLS WITH BISPECIFIC ANTIBODIES AND FC FUSIONS
#246Inert format
#247Binding molecules that modulate a biological activity expressed by a cell
#248Methods of administering anti-OX40 antibodies
#249Compositions and methods for immunotherapy
#250PARTIAL AGONISTS OF INTERLEUKIN-2
#251Proteinaceous heterodimer and use thereof
#252Bispecific antibodies against HER2 and CD3
#253Vectors comprising nucleic acids encoding anti-OX40 antibodies
#254Anti-TIGIT antibodies
#255B7-H4 antibodies and methods of use thereof
#256Antibody variants
#257HUMAN IMMUNE THERAPIES USING A CD27 AGONIST ALONE OR IN COMBINATION WITH OTHER IMMUNE MODULATORS
#258Bispecific antigen binding molecule for a costimulatory TNF receptor
#259GPRC5D chimeric antigen receptors and cells expressing the same
#260Heterodimeric antibodies that bind CD3 and PSMA
#261Humanized or chimeric CD3 antibodies
#262Polypeptides
#263Antibodies against TIM3 and uses thereof
#264FGL2 antibodies and binding fragments thereof and uses thereof
#265Human anti-PD-1, PD-L1, and PD-L2 antibodies and uses therefor
#266Anti-PD-1 antibodies, antigen-binding portions thereof and checkpoint regulator antogonists comprising the same
#267CD47 BLOCKADE THERAPY
#268Anti-PVRIG antibodies and methods of use
#269Anti-human interleukin-2 antibodies and uses thereof
#270Monoclonal Antibodies to Programmed Death 1 (PD-1)
#271Engraftment of stem cells with a combination of an agent that targets stem cells and modulation of immunoregulatory signaling
#272Bispecific heterodimeric fusion proteins containing IL-15-IL-15Ralpha Fc-fusion proteins and immune checkpoint antibody fragments
#273HUMANIZED OR CHIMERIC CD3 ANTIBODIES
#274Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereof
#275Anti-IGF-I receptor antibodies, encoding nucleic acid molecules and methods of using said antibodies
#276Antibody-cytokine engrafted proteins and methods of use for immune related disorders
#277Anti-CD27 and anti-PD-L1 antibodies and bispecific constructs
#278Neutralizing anti-influenza binding molecules and uses thereof
#279Vista antagonist and methods of use
#280Vista modulators for diagnosis and treatment of cancer
#281Monoclonal antibodies against c-Met
#282Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereof
#283Method of treating gastric cancer with anti-FGFR2-IIIb antibodies and modified FOLFOX6 chemotherapy
#284TRISPECIFIC ANTIGEN BINDING PROTEINS
#285HUMAN MONOCLONAL ANTIBODIES TO PROGRAMMED DEATH LIGAND 1 (PD-L1)
#286Bifunctional fusion proteins to inhibit angiogenesis in tumor microenvironment and to activate adaptive immune responses and the genes and uses thereof
#287Anti-CD40 antibodies
#288IL15/IL15Ralpha HETERODIMERIC Fc-FUSION PROTEINS
#289Anti-CD112R compositions and methods
#290Interferon receptor 1 antibodies and their uses
#291Antibodies Against Human NKG2D and Uses Thereof
#292Anti PD-L1 antibodies
#293Anti PD-1 antibodies
#294Antibodies that bind human CD39 and inhibit ATPase activity of a soluble extracellular domain human CD39 polypeptide
#295Anti-vista antibodies and fragments
#296Anti-CD40 antibody
#297Bispecific anti-PSMA X anti-CD28 antibodies and uses thereof
#298Bispecific signaling agents and uses thereof
#299DISTINGUISHING ANTAGONISTIC AND AGONISTIC ANTI B7-H1 ANTIBODIES
#300Nucleic acids encoding anti-OX40 antibodies